Funding spreads across a widening obesity drug pipeline

Investors seeking access to next-generation obesity drugs are either writing checks for proven GLP-1 biology or venturing into riskier, less crowded corners of the obesity drug pipeline, per a new PitchBook report.

• GLP-1 drugs are commercially validated but come with side effects that contribute to discontinuation rates.